查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800223

兽医疫苗市场－2025年至2030年的预测

Veterinary Vaccines Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 151 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

兽用疫苗市场预计将从 2025 年的 93.54 亿美元成长到 2030 年的 137.58 亿美元，复合年增长率为 8.02%。

预计2025年至2030年间，兽用疫苗市场将经历显着增长，这主要得益于人畜共通感染疾病的增加、全球宠物拥有量的增加以及畜牧产品需求的不断增长。减毒活病毒疫苗疫苗，包括减毒活疫苗、灭活疫苗、重组疫苗等，对于预防伴侣动物和农业动物的疾病感染，保护动物和人类的健康至关重要。这些疫苗主要透过肠外给药，在动物保健产业中至关重要。儘管严格的监管可能是一个挑战，但政府的倡议和向预防性医疗保健的转变支撑着市场的发展。

市场驱动因素

通用感染疾病的兴起

人畜共通感染疾病的增加是兽用疫苗市场的主要驱动力。动物可以传播细菌、病毒、寄生虫和真菌等病原体，这些病原体会导致人类患上从轻微到致命的严重疾病。全球通用感染疾病的负担凸显了对有效兽用疫苗的需求，以预防动物间传播。政府倡议，例如针对动物病毒爆发的项目，透过推广疫苗接种作为主要预防措施，进一步推动了市场成长。这些措施在牲畜和宠物数量较多的地区尤其重要，因为这些地区的通用感染疾病的风险较高。

印度需求不断成长

印度兽用疫苗市场正稳步增长，这得益于人口增长和饮食习惯变化推动的肉类和乳製品等畜产品需求的不断增长。家禽和酪农对印度农业经济的贡献巨大，它们越来越多地采用疫苗来预防感染疾病并确保牲畜健康。农民对疫苗接种经济效益的认识不断提高，加上国家动物疾病控制计划等政府项目，也推动了市场扩张。需求旺盛的疫苗包括针对鼠疫、掠食动物病（PPR）、布氏桿菌属和口蹄疫（FMD）的疫苗，这反映出人们对牲畜健康的重视。

宠物拥有量增加

全球范围内，宠物饲养人数呈上升趋势，尤其是猫狗等伴侣动物。伴随这一趋势，宠物护理支出也随之增长，因为饲主更加重视预防性医疗保健，以保护宠物并降低通用感染疾病的风险。尤其是猫咪的日益普及，也促进了宠物护理市场的成长，因为饲主会寻求疫苗接种来确保宠物的健康和安全。

市场限制

兽用疫苗市场面临严格的疫苗核准监管政策的挑战，这可能会延迟疫苗的上市时间并增加上市成本。虽然这些法规确保了疫苗的安全性和有效性，但也限制了创新和可近性，尤其是对小型製造商而言。此外，先进疫苗的高成本可能会限制开发中国家等价格敏感市场的采用。透过简化的监管流程和经济高效的疫苗开发来应对这些挑战，对于市场持续成长至关重要。

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章：动物疫苗市场（依疫苗类型）

  • 介绍
  • 减毒活疫苗
  • 惰性疫苗
  • 类毒素疫苗
  • 次单位疫苗和结合疫苗
  • 其他的

6. 动物疫苗市场（依给药方式）

  • 介绍
  • 口服
  • 肠外给药
  • 其他的

7. 兽用疫苗市场（依动物类型）

  • 介绍
  • 伴侣动物
  • 家畜
    • 牛
    • 家禽
    • 猪
    • 其他的

第 8 章：兽用疫苗市场（按地区）

  • 介绍
  • 北美洲
    • 按疫苗类型
    • 按给药方式
    • 依动物类型
    • 按国家
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按疫苗类型
    • 按给药方式
    • 依动物类型
    • 按国家
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按疫苗类型
    • 按给药方式
    • 依动物类型
    • 按国家
      • 德国
      • 法国
      • 英国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 按疫苗类型
    • 按给药方式
    • 依动物类型
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 以色列
      • 其他的
  • 亚太地区
    • 按疫苗类型
    • 按给药方式
    • 依动物类型
    • 按国家
      • 中国
      • 印度
      • 日本
      • 韩国
      • 印尼
      • 其他的

第九章：竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章：公司简介

  • Elanco
  • Zoetis Inc.
  • Ceva
  • Merck Animal Health
  • Phibro Animal Health Corporation
  • Virbac
  • Hester Bioscience Limited
  • Hipra
  • Boehringer Ingelheim International GmbH
  • AdvaCare Pharma

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061611783

The veterinary vaccines market is expected to grow from USD9.354 billion in 2025 to USD13.758 billion in 2030, at a CAGR of 8.02%.

The veterinary vaccines market is projected to experience significant growth from 2025 to 2030, driven by the rising prevalence of zoonotic diseases, increasing global pet adoption, and growing demand for livestock products. Veterinary vaccines, including live attenuated, inactivated, recombinant, and other types, are critical for preventing disease transmission in companion and agricultural animals, protecting both animal and human health. Administered primarily through parenteral methods, these vaccines are essential in the veterinary healthcare industry. The market is supported by government initiatives and a shift toward preventive healthcare, though stringent regulations may pose challenges.

Market Drivers

Rising Zoonotic Diseases

The increasing incidence of zoonotic diseases is a primary driver of the veterinary vaccines market. Animals can transmit pathogens such as bacteria, viruses, parasites, and fungi, which cause serious illnesses in humans, ranging from mild to fatal. The global burden of zoonotic diseases underscores the need for effective veterinary vaccines to prevent transmission from animals to humans. Government initiatives, such as programs targeting animal virus outbreaks, further boost market growth by promoting vaccination as a key preventive measure. These efforts are particularly critical in regions with high livestock and pet populations, where zoonotic risks are elevated.

Growing Demand in India

The Indian veterinary vaccines market is experiencing steady growth, driven by rising demand for livestock products like meat and dairy, fueled by population growth and changing dietary habits. The poultry and dairy sectors, major contributors to India's agricultural economy, are increasingly adopting vaccines to prevent infectious diseases and ensure healthy animal populations. Farmers' growing awareness of the economic benefits of vaccination, coupled with government programs like the National Animal Disease Control Programme, supports market expansion. High-demand vaccines include those for Peste des petits ruminants (PPR), Brucella, and Foot and Mouth Disease (FMD), reflecting the focus on livestock health.

Increasing Pet Adoption

Global pet adoption rates are rising, particularly for companion animals like dogs and cats, driving demand for veterinary vaccines. This trend is accompanied by increased pet care expenditures, as owners prioritize preventive healthcare to protect their pets and reduce zoonotic risks. The growing popularity of cats, in particular, is contributing to market growth, as pet owners seek vaccines to ensure animal health and safety.

Market Restraints

The veterinary vaccines market faces challenges due to stringent regulatory policies governing vaccine approvals, which can delay market entry and increase development costs. These regulations, while ensuring safety and efficacy, may limit innovation and accessibility, particularly for smaller manufacturers. Additionally, the high cost of advanced vaccines can restrict adoption in price-sensitive markets, such as developing regions, where affordability is a key concern. Addressing these challenges through streamlined regulatory processes and cost-effective vaccine development will be critical for sustained market growth.

Market Segmentation

By Product Type

The market includes live attenuated, inactivated, recombinant, and other vaccines. Parenteral administration dominates due to its effectiveness in delivering targeted immunity. Recombinant vaccines are gaining traction for their precision and safety in addressing specific pathogens.

By Animal Type

The market serves companion animals (e.g., dogs, cats) and agricultural animals (e.g., cattle, poultry). The companion animal segment is growing rapidly due to rising pet ownership, while the agricultural segment remains significant, driven by the need to maintain livestock health and productivity.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America leads due to high pet care spending and advanced veterinary infrastructure. Asia-Pacific, particularly India, is expected to grow steadily, driven by increasing livestock production and government support. Europe, South America, and the Middle East and Africa are also poised for growth, supported by rising awareness and improving veterinary services.

The veterinary vaccines market is set for robust growth from 2025 to 2030, driven by rising zoonotic disease risks, growing pet adoption, and increasing demand for livestock products, particularly in India. Despite challenges from stringent regulations and high costs, the market's outlook remains positive, with strong growth in North America and Asia-Pacific. Industry players must focus on innovative, cost-effective vaccines and regulatory compliance to capitalize on the growing demand for preventive animal healthcare solutions.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Vaccine Type

  • Live, Attenuated Vaccines
  • Inactivated/Killed Vaccines
  • Toxoid Vaccines
  • Subunit & Conjugate Vaccines
  • Others

By Mode of Administration

  • Oral
  • Parental
  • Others

By Animal

  • Companion Animals
  • Livestock Animals
  • Cattle
  • Poultry
  • Swine
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • UK
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. VETERINARY VACCINE MARKET BY VACCINE TYPE

  • 5.1. Introduction
  • 5.2. Live Attenuated Vaccine
  • 5.3. Inactive/Killed Vaccine
  • 5.4. Toxoid Vaccine
  • 5.5. Subunit & Conjugate Vaccine
  • 5.6. Others

6. VETERINARY VACCINE MARKET BY MODE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Parental
  • 6.4. Others

7. VETERINARY VACCINE MARKET BY ANIMAL TYPE

  • 7.1. Introduction
  • 7.2. Companion Animals
  • 7.3. Livestock Animals
    • 7.3.1. Cattle
    • 7.3.2. Poultry
    • 7.3.3. Swine
    • 7.3.4. Others

8. VETERINARY VACCINE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Vaccine Type
    • 8.2.2. By Mode of Administration
    • 8.2.3. By Animal Type
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Vaccine Type
    • 8.3.2. By Mode of Administration
    • 8.3.3. By Animal Type
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Vaccine Type
    • 8.4.2. By Mode of Administration
    • 8.4.3. By Animal Type
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Vaccine Type
    • 8.5.2. By Mode of Administration
    • 8.5.3. By Animal Type
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Israel
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Vaccine Type
    • 8.6.2. By Mode of Administration
    • 8.6.3. By Animal Type
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. India
      • 8.6.4.3. Japan
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Elanco
  • 10.2. Zoetis Inc.
  • 10.3. Ceva
  • 10.4. Merck Animal Health
  • 10.5. Phibro Animal Health Corporation
  • 10.6. Virbac
  • 10.7. Hester Bioscience Limited
  • 10.8. Hipra
  • 10.9. Boehringer Ingelheim International GmbH
  • 10.10. AdvaCare Pharma

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations